Global Hospital-Acquired Infection Control Market 2017-2021

This industry research report identifies AstraZeneca, GlaxoSmithKline, Merck, and Pfizer as the key vendors in the global hospital-acquired infection control market. A comprehensive analysis of this market is also presented by infection type (CAUTIs, SSIs, CLABSIs, and respiratory infections), by end-user (hospitals and ICUs, outpatient care centers, LTCFs, and others), and by geography (the Americas, APAC, and EMEA).

Hospital-acquired infection control market forecasts

Market research analysts at Technavio predict that the global hospital-acquired infection control market will grow steadily at a CAGR of around 5% by 2021. The adoption of data analytics to improve healthcare facilities is identified as one of the primary growth factors for this market. Data analytics refers to the collection of tools and techniques that are used to generate insights and take actions based on real-time data.

Over the years, the healthcare systems have been collecting data through electronic medical records (EMRs) and electronic health records (EHRs). When this data is analyzed using numerous data analytics techniques, it helps reach valuable conclusions and deductions that can be used to improve healthcare settings and even reduce the prevalence of hospital-acquired infection (HAIs). Several information technology companies are employing various algorithms to arrive at inferences that could help improve hospital-acquired infection control. Additionally, government organizations also use data analytics to improve their measures to tackle hospital-acquired infections.

Get A Free Sample 

HAI control market growth based on geography

In terms of geographic regions, the Americas will be the major revenue contributor to the hospital-acquired infection control market throughout the forecast period. The increase in hospital-acquired infection research and the launch of new products drive the market’s growth in this region. Moreover, the rise in government initiatives to combat the rising occurrences of hospital-acquired infections will also boost the growth of the hospital-acquired infection control market in this region.  

Hospital-acquired infection control market worth: Competitive landscape and key vendors  

The hospital-acquired infection control market is quite competitive and consists of leading pharmaceutical companies who account for most of the market shares. Companies with limited experience are developing innovative solutions to control hospital-acquired infections. Investments in the manufacturing to expand production facilities and considerable efforts to develop advanced drugs that can cure hospital-acquired infections are the key strategies employed by the market players. To expand the customer base, some key companies are also focusing on launching products with equitable prices that can be profitable for the company and affordable for the patients.

The leading vendors in the HAI market

• AstraZeneca
• GlaxoSmithKline
• Merck
• Pfizer

Hospital-acquired infection control market segmentation by infection type

• Catheter-associated urinary tract infections (CAUTIs)
• Surgical site infections (SSIs)
• Central line-associated bloodstream infections (CLABSIs)
• Respiratory infections

During 2016, the CAUTIs segment accounted for the major shares of the hospital-acquired infection control market. Factors such as the increase in the number of hospital admissions due to urinary tract infections (UTIs) and the improper maintenance of healthcare facilities, will contribute to the growth of this industry segment in the coming years.

Hospital-acquired infection control market forecast by end-user

• Hospitals and ICUs
• Outpatient care centers
• Long-term care facilities (LTCFs)

As per this market research report, hospitals and ICUs held the maximum market share of the hospital-acquired infection control market during 2016. The prevalence of hospital-acquired infections is high in hospitals and ICUs as they lack adequate maintenance due to the high volume of patients and limited budgets. Moreover, the staff shortage in hospitals and ICUs also increases the prevalence of HAIs as patients do not get the required attention. These factors will drive the growth in demand for hospital-acquired infections control products from hospitals and ICUs during the forecast period.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global hospital-acquired infection control market?
• What are the key market trends impacting the growth of the global hospital-acquired infection control market?
• What are the challenges to market growth?
• Who are the key vendors in the global hospital-acquired infection control market?
• What are the market opportunities and threats faced by the vendors in the global hospital-acquired infection control market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global hospital-acquired infection control market?

Technavio also offers customization on reports based on specific client requirement.